8-K: Crinetics Pharmaceuticals Stockholders Re-Elect Directors, Ratify Auditor, and Approve Executive Compensation at Annual Meeting

Crinetics Pharmaceuticals, Inc. announced that its stockholders approved the election of three Class I directors, ratified BDO USA, P.C. as its independent accounting firm, and approved executive compensation on an advisory basis at its annual meeting held on June 11, 2025.

Summary

• The annual meeting of stockholders of Crinetics Pharmaceuticals, Inc. was held online via live audio webcast on June 11, 2025.
• Approximately 95% of total outstanding shares, or 88,931,596 shares, were present virtually or by proxy at the Annual Meeting.
• Stockholders approved the election of R. Scott Struthers, Ph.D., Matthew K. Fust, and Rogrio Vivaldi Coelho, M.D. as Class I directors to the Board of Directors for three-year terms, set to expire at the 2028 annual meeting of stockholders.
• The votes for the elected directors were: R. Scott Struthers, Ph.D. (69,586,919 For, 15,729,147 Withheld), Matthew K. Fust (67,615,092 For, 17,700,974 Withheld), and Rogrio Vivaldi Coelho, M.D. (68,864,528 For, 16,451,538 Withheld), with 3,615,529 broker non-votes for each director.
• The selection of BDO USA, P.C. as the Company's independent registered accounting firm for the fiscal year ending December 31, 2025, was ratified by stockholders with 88,742,805 votes For, 129,064 Against, and 59,727 Abstentions.
• Stockholders approved, on an advisory basis, the compensation of the Company's named executive officers with 82,658,715 votes For, 2,636,436 Against, and 20,915 Abstentions, along with 3,615,529 broker non-votes.

Sentiment

Score: 8

Explanation: The sentiment is positive as all proposals presented at the annual meeting were approved by stockholders with strong support, indicating stability and alignment between management and shareholders on key governance matters.

Positives

• All three proposals presented at the Annual Meeting were approved by the stockholders with significant majorities.
• High stockholder participation was observed, with approximately 95% of total outstanding shares represented at the meeting.
• The re-election of all proposed Class I directors ensures continuity and stability in the Board of Directors for the next three years.
• The ratification of the independent accounting firm provides assurance of continued robust financial oversight and compliance.
• Advisory approval of executive compensation indicates stockholder alignment and satisfaction with current compensation practices for named executive officers.

Future Outlook

The document primarily reports on the outcomes of stockholder votes and does not provide forward-looking statements regarding the company's financial performance or strategic direction, beyond the terms of elected directors and auditor engagement.

Management Comments

• R. Scott Struthers, Ph.D., President and Chief Executive Officer, signed the report on behalf of Crinetics Pharmaceuticals, Inc.

Industry Context

This 8-K filing details routine corporate governance matters, specifically the outcomes of an annual stockholder meeting. Such filings are standard for publicly traded companies and reflect compliance with SEC regulations rather than specific industry trends or competitive developments.

Comparison to Industry Standards

• This filing pertains to standard corporate governance practices, such as director elections and auditor ratification, which are common across all publicly traded companies.
• The high voter turnout (approximately 95%) and overwhelming approval of all management-backed proposals are generally indicative of strong shareholder support, which is a positive sign compared to companies facing significant shareholder dissent or activist campaigns.

Corporate Governance

Stakeholder Impact

• Shareholders: Approved key governance proposals, including director elections, auditor ratification, and executive compensation, indicating general satisfaction with current corporate direction and oversight.
• Management: Received a vote of confidence from shareholders through the approval of director re-elections and executive compensation, reinforcing their mandate.

Next Steps

• The elected Class I directors (R. Scott Struthers, Matthew K. Fust, and Rogrio Vivaldi Coelho) will serve three-year terms expiring at the 2028 annual meeting of stockholders.
• BDO USA, P.C. will serve as the independent registered accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Keywords

Crinetics Pharmaceuticals, CRNX, Annual Meeting, Stockholder Vote, Director Election, Corporate Governance, Auditor Ratification, Executive Compensation, SEC Filing, 8-K